Medikamentöse Kombinationsbehandlung bei Patienten mit Pulmonal arterieller Hypertonie

Zusammenfassung

In den letzten Jahren konnten wesentliche Fortschritte in der medikamentösen Behandlung der Pulmonal-arteriellen Hypertonie (PAH) erreicht werden. Eine Vielzahl von Patienten bedarf aufgrund hämodynamischer und klinischer Befunde im Verlauf einer Kombinationstherapie. Obwohl die einzelnen Substanzen lediglich in der Monotherapie im Rahmen der Zulassungsstudien geprüft wurden, existiert mittlerweile eine ausreichende Evidenz zur sicheren und wirksamen Kombinationsbehandlung. Die hierbei zugrunde liegenden Untersuchungen werden in einer kurzen Übersicht aufgeführt und kommentiert.

Summary

Despite recent remarkable efforts in the medical treatment options of patients with pulmonary arterial hypertension (PAH) a considerable number of patients need escalations to improve disease related symptoms and pulmonary hemodynamics. Most of the pulmonary vascular vasodilators have been approved in its potency as an initial and sole medical option. However, there is increasing scientific evidence on the reliability, safety and effectiveness of possible combinations. This paper reviews the current scientific literature about medical escalations and combination therapy in patients with PAH.

Schlüsselwörter

pulmonal arterielle Hypertonie - medikamentöse Behandlung - Kombinationstherapie - klinische Studien

Key words

pulmonary arterial hypertension - medical treatment - combination therapy - clinical studies

Literatur

• 1 Badesch D B, Abman S H, Simonneau G, Rubin L J, McLaughlin V V. Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines.  Chest. 2007;  131 1917-1928
• 2 Benza R L, Barst R J, Galie N. et al .Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A One Year, Prospective, Open Label, Observation of Outcome and Survival. CHEST 2008, Juli 14. [Epub ahead of print]
• 3 Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension.  Swiss Med Wkly. 2006;  136 114-118
• 4 Chin K M, Rubin L J. Pulmonary arterial hypertension.  J Am Coll Cardiol. 2008;  51 1527-1538
• 5 Dandel M, Lehmkuhl H B, Mulahasanovic S. et al . Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.  J Heart Lung Transplant. 2007;  26 898-906
• 6 Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, Soongswang J, Chanthong P, Nana A. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease.  J Med Assoc Thai. 2005;  88 Suppl 8 S60-S65
• 7 Ghofrani H A, Rose F, Schermuly R T. et al . Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.  J Am Coll Cardiol. 2003;  42 158-164
• 8 Ghofrani H A, Wiedemann R, Rose F. et al . Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.  Ann Intern Med. 2002;  136 515-522
• 9 Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.  Am J Cardiol. 2005;  96 1334-1336
• 10 Grünig E, Michelakis E, Vachiery J, Vizza C, Meyer J, Galie N. Acute administration of sildenafil in patients with pulmonary arterial hypertension (PAH) treated with bosentan produced a significant hemodynamic response: results of the COMPASS-1 study.  Eur Heart J. 2007;  28 (Suppl.) A140
• 11 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-10
• 12 Hoeper M M, Leuchte H, Halank M. et al . Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.  Eur Respir J. 2006;  28 691-694
• 13 Hoeper M M, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 14 Humbert M, Barst R J, Robbins I M. et al . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
• 15 Humbert M, Segal E S, Kiely D G, Carlsen J, Schwierin B, Hoeper M M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007 30: 338-344
• 16 Mathai S C, Girgis R E, Fisher M R. et al . Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.  Eur Respir J. 2007;  29 469-475
• 17 McLaughlin V V, Oudiz R J, Frost A. et al . Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  174 1257-1263
• 18 McLaughlin V V, Rubin L, Benza R. et al . TRIUMPH I: Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH).  Am J Respir Crit Care Med. 2008;  177 (Suppl.) A965
• 19 Miwa K, Matsubara T, Uno Y. et al . Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome.  Int Heart J. 2007;  48 417-422
• 20 O’Callaghan D, Gaine S P. Combination therapy and new types of agents for pulmonary arterial hypertension.  Clin Chest Med. 2007;  28 169-185
• 21 Olschewski H, Hoeper M M, Borst M M. et al . [Diagnosis and therapy of chronic pulmonary hypertension].  Clin Res Cardiol. 2007;  96 301-330
• 22 Ruiz M J, Escribano P, Delgado J F. et al . Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.  J Heart Lung Transplant. 2006;  25 1353-1357
• 23 Seyfarth H J, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.  Chest. 2005;  128 709-713
• 24 Simonneau G, Rubin L, Galie N. et al . Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension (PAH).  Am J Respir Crit Care Med. 2007;  175 (Suppl.) A300
• 25 Wilkens H, Guth A, Konig J. et al . Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension.  Circulation. 2001;  104 1218-1222